Skip to main content

Table 2 Spearman’s correlations of CETP activity and PCSK9 levels with clinical and metabolic variables

From: Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

  CETP PCSK9
  r P r P
CETP 1.000 0.256a <0.0001
PCSK9 0.256a <0.0001 1.000
Age −0.088 0.063 0.045 0.346
BMI 0.020 0.679 0.052 0.268
SBP 0.208 <0.0001 0.123 0.022
DBP 0.129 0.016 0.085 0.112
Cholesterol 0.585 <0.0001 0.194 <0.0001
Triglycerides 0.491 <0.0001 0.210 <0.0001
LDL-C 0.412 <0.0001 0.179 <0.0001
HDL-C 0.134 0.004 0.109 0.021
ApoB100 0.494 <0.0001 0.194 <0.0001
ApoA1 −0.002 0.970 0.135 0.004
Glucose 0.186 <0.0001 0.215 <0.0001
LCAT −0.251 <0.0001 −0.072 0.127
Lp particles number
 Total VLDL 0.419 <0.0001 0.176 <0.0001
 Large VLDL 0.411 <0.0001 0.160 0.001
 Medium VLDL 0.413 <0.0001 0.172 <0.0001
 Small VLDL 0.420 <0.000 0.177 <0.0001
 Total LDL 0.300 <0.0001 0.134 0.004
 Large LDL 0.246 <0.0001 0.093 0.049
 Medium LDL 0.234 <0.0001 0.111 0.019
 Small LDL 0.332 <0.0001 0.152 0.001
 Total HDL 0.098 0.038 0.024 0.614
 Large HDL 0.109 0.021 0.043 0.359
 Medium HDL −0.193 <0.0001 −0.044 0.356
 Small HDL 0.241 <0.0001 0.071 0.136
Lp size
 VLDL −0.276 <0.0001 −0.114 0.015
 LDL −0.200 <0.0001 −0.107 0.023
 HDL −0.362 <0.0001 −0.104 0.027
  1. aAfter adjusting PCSK9 for age, gender, BMI, SBP, LDL-C, triglycerides and glucose, the Spearman’s correlation with CETP remained significant (r = 0.158, P = 0.003)
  2. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C LDL cholesterol, HDL-C HDL cholesterol